Amass Brands (AMSS) · Oct 14, 2026 · Delisting
Nasdaq deficiency — Below $1.00 for 30 business days; cure deadline April 7, 2027
AMASS Brands received a Nasdaq deficiency notice after 30 days below $1, adding a second listing hurdle ahead of its January 2027 market-value deadline.
AMASS is a recently Nasdaq-listed, multi-category beverage company selling alcoholic and non-alcoholic brands through wholesale and online channels; it is still building scale after its May 2026 direct listing. This filing adds a second, separate Nasdaq problem. The company failed the $1 minimum bid-price rule after its stock closed below $1 for 30 consecutive business days from August 26 through October 8.
| Requirement | Status / deadline |
|---|---|
| Nasdaq minimum bid price | Below $1.00 for 30 consecutive business days |
| First cure period | Through April 7, 2027 |
| Required recovery | At least $1.00 closing bid for 10 consecutive business days |
| Previously disclosed MVLS/MVPHS deficiency | Compliance deadline January 19, 2027 |
The immediate consequence is limited, but the capital-markets risk is materially higher. Nasdaq has not suspended or delisted the shares now, and AMASS has 180 calendar days to restore the bid price. 〔0〕 But this is not a standalone warning: the company already had separate deficiencies involving the market value of listed securities and publicly held shares, with an earlier January 19, 2027 deadline. 〔1〕
The path to preserving the listing is now more demanding than the company’s framing suggests. If AMASS cannot regain the bid-price requirement by April 7, it may seek a second 180-day period by transferring to Nasdaq’s Capital Market, but only if it satisfies that market’s other listing standards. Failure across the available periods would make the common stock subject to delisting. 〔2〕 That makes the January market-value deadline the nearer test, while the new bid-price deficiency adds another condition that could complicate future financing, liquidity, and investor access.
Bottom line: This does not change AMASS’s beverage operations today, but it meaningfully weakens the company’s listing and financing position. The market already knew AMASS had one Nasdaq deficiency; the new sub-$1 notice makes the compliance problem broader and more urgent, not routine confirmation.
MVLS/MVPHS compliance deadline, January 19, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!